QHSLab, Inc. (USAQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QHSLab, Inc. (USAQ) trades at $0.35 with AI Score 62/100 (Grade B+). QHSLab, Inc. is a medical device technology and SaaS company focused on value-based healthcare and personalized medicine. Market cap: $5.26M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for USAQ: USAQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates USAQ against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
USAQ: 2/3 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
QHSLab, Inc. (USAQ) Healthcare & Pipeline Overview
QHSLab, Inc. specializes in medical device technology and SaaS solutions, offering innovative products for chronic disease management and personalized medicine, positioning itself as a key player in the evolving landscape of value-based healthcare.
What Is the Investment Thesis for USAQ?
QHSLab, Inc. presents a unique investment thesis driven by its focus on value-based healthcare and innovative product offerings. The company boasts a profit margin of 15.6% and a gross margin of 66.7%, indicating strong operational efficiency. With a return on equity (ROE) of 93.2%, QHSLab demonstrates effective use of shareholder equity to generate profits. The strategic alliance with Medical License Factory, LLC, is expected to enhance its market presence and expand its product portfolio, particularly in the digital therapeutics space. Additionally, the growing demand for remote patient monitoring solutions and chronic disease management presents a significant growth opportunity. As healthcare shifts toward value-based models, QHSLab's focus on prevention and early detection aligns well with market trends, potentially leading to increased adoption of its products. However, the company's high debt-to-equity ratio of 8.56 may pose risks, necessitating careful monitoring of its financial health as it pursues growth initiatives.
Based on FMP financials and quantitative analysis
USAQ Key Highlights
Market Cap of $5.26M reflects a niche position in the healthcare technology sector.
- Profit margin of 15.6% indicates effective cost management and operational efficiency.
- Gross margin of 66.7% significantly exceeds industry averages, showcasing strong pricing power.
- Return on equity (ROE) of 93.2% highlights exceptional profitability relative to shareholder equity.
- Strategic alliance with Medical License Factory, LLC aims to enhance product offerings and market reach.
Who Are USAQ's Competitors?
USAQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| SYK Stryker Corporation | $340.11 | +0.04% | $131B | 79 |
| ABT Abbott Laboratories | $114.46 | +1.58% | $198B | 70 |
| CNVIF Conavi Medical Corp. | $0.15 | +2.16% | $12.6M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.08 | -0.97% | $14.4M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -2.90% | $24.9M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are USAQ's Key Strengths?
Innovative product offerings in a growing healthcare market.
- Strong profit margins and return on equity.
- Strategic alliances to enhance market reach.
What Are USAQ's Weaknesses?
Small workforce limits operational capacity.
- High debt-to-equity ratio may pose financial risks.
- Limited brand recognition compared to larger competitors.
What Could Drive USAQ Stock Higher?
Expansion of product offerings through strategic partnerships.
- Development of the QHSLab system to enhance healthcare informatics.
- Increasing demand for remote patient monitoring solutions.
- Entry into new geographic markets to capture additional market share.
What Are the Key Risks for USAQ?
Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
- Regulatory challenges affecting product approvals.
- Intense competition from larger medical device manufacturers.
- Economic downturns impacting healthcare spending.
What Are the Growth Opportunities for USAQ?
- QHSLab's development of digital therapeutics aligns with this trend, positioning the company to capture a share of this expanding market. Its focus on algorithmic personalized medicine enhances its competitive advantage, enabling tailored solutions for chronic disease management.
- Growth opportunity 2: With the rise of value-based care models, healthcare providers are increasingly seeking solutions that promote prevention and early detection. QHSLab's products, such as the QHSLab system, are designed to meet this demand, providing healthcare organizations with tools to improve patient outcomes. This alignment with industry trends presents a significant growth opportunity for QHSLab.
- QHSLab's point-of-care solutions are well-positioned to capitalize on this trend, offering healthcare providers the ability to monitor patients remotely and effectively manage chronic diseases, which could lead to increased adoption of its products.
- Growth opportunity 4: The increasing prevalence of chronic diseases globally presents a substantial market opportunity for QHSLab. With chronic diseases accounting for 60% of global deaths, the demand for innovative solutions that promote management and reversal of these conditions is on the rise. QHSLab's focus on chronic care aligns with this need, potentially driving revenue growth.
- Growth opportunity 5: QHSLab's strategic alliance with Medical License Factory, LLC, opens avenues for collaboration and expansion into new markets. This partnership can enhance product offerings and improve market penetration, providing QHSLab with a competitive edge in the healthcare technology landscape.
What Are USAQ's Competitive Advantages?
- Strong focus on value-based healthcare differentiates QHSLab from competitors.
- Innovative product offerings in digital therapeutics and remote monitoring.
- Strategic alliances enhance market presence and product development.
What Does USAQ Do?
Founded in 1983 and based in West Palm Beach, Florida, QHSLab, Inc. began its journey as USA Equities Corp. and rebranded in April 2022 to reflect its focus on healthcare technology. The company operates at the intersection of medical devices and software as a service (SaaS), concentrating on value-based healthcare, informatics, and algorithmic personalized medicine. QHSLab develops digital therapeutics and point-of-care solutions that facilitate remote patient monitoring and address chronic care needs. One of its flagship offerings is the Quality Health Score Lab (QHSLab), a cloud-based SaaS system that enables healthcare providers to securely capture and store patient information. Additionally, QHSLab distributes AllergiEnd, a diagnostic product related to allergen immunotherapy treatments, primarily targeting primary care physicians. The company’s innovative products are designed to enhance prevention, early detection, management, and potential reversal of chronic diseases, reflecting a commitment to improving patient outcomes. With a strategic alliance with Medical License Factory, LLC, QHSLab is positioned to leverage partnerships to expand its market reach and enhance its product offerings. Despite its small workforce of four employees, QHSLab is poised to make significant contributions to the healthcare technology sector as it continues to innovate and adapt in a rapidly changing industry.
What Products and Services Does USAQ Offer?
- Develops medical device technology and SaaS solutions for healthcare.
- Offers digital therapeutics and point-of-care solutions for chronic disease management.
- Provides the QHSLab system, a cloud-based platform for secure patient information storage.
- Distributes AllergiEnd, a diagnostic product for allergen immunotherapy treatments.
- Focuses on value-based healthcare and algorithmic personalized medicine.
- Supports remote patient monitoring to improve patient outcomes.
How Does USAQ Make Money?
- Generates revenue through the sale of medical devices and SaaS subscriptions.
- Offers diagnostic products and treatments to healthcare providers.
- Partners with organizations to expand market reach and product offerings.
- Focuses on value-based healthcare solutions to align with industry trends.
What Industry Does USAQ Operate In?
The medical device industry is experiencing significant growth, driven by advancements in technology and an increasing focus on value-based healthcare. QHSLab, Inc. operates within this expanding market, emphasizing digital therapeutics and SaaS solutions that cater to the growing demand for remote patient monitoring and chronic disease management. The competitive landscape includes various players, but QHSLab's focus on personalized medicine and informatics positions it uniquely to capitalize on emerging trends in healthcare technology.
Who Are USAQ's Key Customers?
- Primary care physicians utilizing QHSLab's diagnostic products.
- Healthcare organizations seeking SaaS solutions for patient information management.
- Patients in need of chronic disease management and digital therapeutics.
Company Profile
QHSLab, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in West Palm Beach, US. The company is led by CEO Troy James Grogan. USAQ has traded publicly since 2013.
Key Financial Metrics
Return on equity for QHSLab, Inc. stands at 51.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 27.1%, showing how much profit it generates from its asset base. USAQ trades at a trailing price-to-earnings ratio of 8.60, below the Healthcare sector average of ~23x. Its free cash flow yield is -2.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.82 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 11.6%, the inverse of the P/E and a quick read on earnings relative to price.
USAQ Valuation & Market Position
With a $5.26M market cap, QHSLab, Inc. sits in the micro-cap segment of the market. Relative to its peer group, USAQ's quantitative score of 62/100 is roughly in line with the peer average of 71/100.
Quarterly Financial Performance: QHSLab, Inc.
Revenue for QHSLab, Inc. came in at $847K during Q2 2026, a 16.3% improvement versus the preceding quarter. The company recorded net income of $38K, with diluted EPS of $0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, USAQ averaged $0.01 in diluted EPS.
Financial Health
QHSLab, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.38 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
QHSLab, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 23.0% below estimates on average.
Forward Outlook
Wall Street analysts project QHSLab, Inc. revenue of about $3.2M for fiscal 2026, with EPS near $0.30.
USAQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recientes compras de acciones por parte de ejecutivos sugieren confianza en el futuro de la empresa.
- El sentimiento en la comunidad ha sido mayormente positivo, con muchos inversores destacando la innovación de QHSLab.
- Se han anunciado nuevas asociaciones estratégicas que podrían expandir su alcance en el mercado.
- Los desarrollos recientes en sus productos han generado expectativas optimistas entre los consumidores y analistas.
Bear Case
- Algunos analistas expresan preocupaciones sobre la sostenibilidad del crecimiento a largo plazo de la empresa.
- El sentimiento negativo en ciertas plataformas sociales indica incertidumbre entre los inversores sobre la dirección futura de QHSLab.
- Recientes críticas sobre la ejecución de la empresa pueden afectar la confianza de los accionistas.
- La competencia en el sector ha aumentado, lo que podría presionar a QHSLab y limitar su crecimiento.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $847,490 | $38,030 | $0.0016 |
| Q1 2026 | $728,685 | -$103,906 | -$0.01 |
| Q4 2025 | $703,810 | $556,573 | $0.03 |
| Q3 2025 | $737,066 | $33,411 | $0.0017 |
Based on FMP financials and quantitative analysis
USAQ Latest News
No recent news available for USAQ.
USAQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for USAQ.
Price Targets
Wall Street price target analysis for USAQ.
USAQ MoonshotScore
What does this score mean?
The MoonshotScore rates USAQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Troy James Grogan
CEO
Troy James Grogan has been leading QHSLab, Inc. since its rebranding in 2022. With a background in healthcare technology, he has been instrumental in steering the company towards innovative solutions in medical devices and SaaS. His leadership experience spans over two decades in various healthcare roles, focusing on value-based care and digital health.
Track Record: Under Grogan's leadership, QHSLab has successfully transitioned to a focus on value-based healthcare, enhancing its product offerings and establishing strategic partnerships. His strategic vision has positioned the company for growth in the evolving healthcare landscape.
USAQ OTC Market Information
QHSLab, Inc. trades on the OTC Other tier, which includes companies that do not meet the requirements for higher tiers like OTCQX or OTCQB. This tier typically has less stringent reporting requirements and is often associated with smaller, less liquid stocks.
- OTC Tier: OTC Other
- Limited financial disclosures may hinder investor confidence.
- Low trading volume could lead to price volatility.
- Higher susceptibility to market manipulation due to lower visibility.
- Verify the company's financial health and operational metrics.
- Assess the regulatory compliance status of its products.
- Investigate the strategic partnerships and their impact on growth.
- Review the competitive landscape and market positioning.
- Evaluate the management team's experience and track record.
- Established in 1983, indicating a long operational history.
- Recent rebranding to QHSLab, Inc. reflects a strategic focus.
- Partnership with Medical License Factory, LLC enhances credibility.
USAQ Healthcare Stock FAQ
What does the AI Score mean for USAQ?
USAQ holds an AI Score of 62/100 (Grade: B+). This is an educational research signal, not a buy or sell recommendation. QHSLab, Inc. is a medical device technology and SaaS company focused on value-based healthcare and personalized medicine. Founded in 1983, it develops innovative solutions for chronic care …
What does QHSLab, Inc. do?
QHSLab, Inc. specializes in medical device technology and software as a service (SaaS) solutions. The company develops products aimed at value-based healthcare, including digital therapeutics, remote patient monitoring solutions, and a cloud-based platform for secure patient information storage. Their offerings, such as the QHSLab system and AllergiEnd, focus on chronic disease management and allergen immunotherapy.
How does QHSLab, Inc. navigate regulatory approval processes?
QHSLab, Inc. navigates regulatory approval processes by ensuring compliance with FDA and other relevant health authorities. The company focuses on meeting rigorous standards for its medical devices and SaaS products, which are essential for gaining market access. Its strategic alliances may also provide additional support in managing regulatory challenges.
What are the main risks for QHSLab, Inc.?
QHSLab, Inc. faces several risks, including regulatory challenges that could impact product approvals and market entry. Additionally, the company operates in a highly competitive landscape, with larger manufacturers posing a threat to its market share. Economic downturns may also affect healthcare spending, impacting demand for its products and services.
What are the key factors to evaluate for USAQ?
QHSLab, Inc. (USAQ) holds an AI score of 62/100 (moderate). presents a unique investment thesis driven by its focus on value-based healthcare and innovative product offerings. Not financial advice.
How frequently does USAQ data refresh on this page?
USAQ's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven USAQ's recent stock price performance?
QHSLab, Inc. (USAQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings in a growing healthcare market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider USAQ overvalued or undervalued right now?
QHSLab, Inc. (USAQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research USAQ before investing?
Before investing in QHSLab, Inc. (USAQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial disclosures may affect the analysis.